Pterygium
Conditions
Keywords
pterygium, bevacizumab, recurrence of pterygium
Brief summary
A pterygium is a fibrovascular growth originating from the conjunctiva that grows onto the surface of the cornea. Frequently, these pterygia will recur even after surgical resection. Bevacizumab is an inhibitor of angiogenesis, which is needed for recurrent growth. The use of bevacizumab is poorly understood in inhibiting pterygium growth. The objective of this study is to compare the effects of wound healing and recurrence rates in postoperative bevacizumab versus pterygium excision alone.
Detailed description
This is a prospective trial. Thirty-one patients with a primary pterygium of at least 2 mm in size and without any previous ocular surgery will be included. Outcome measures will include best corrected visual acuity, intraocular pressure, recurrence, and any sight threatening complications at two weeks, two months, and six months postoperatively.
Interventions
DRUGBevacizumab
Sponsors
Arrowhead Regional Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* any patient 18 years of age or older with a primary pterygium that extends at least 2 mm past the limbus
Exclusion criteria
* history of glaucoma * previous ocular surgery * steroid-response glaucoma * previous myocardial infarct * bleeding disorder * pregnancy * lack of patient cooperation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| number of recurrent pterygia with postoperative bevacizumab | 6 months | The number of recurrent pterygia with patients who received bevacizumab after pterygium excision was compared to the number of recurrences in those patients who only had pterygium excision. |
Countries
United States
Outcome results
None listed